Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
{\displaystyle {\begin{aligned}&{\frac {\mathbf {D} m}{\mathbf {Dt} }}=\iiint \limits _{V}\left({\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot \mathbf {u} )\right)\,dV\\[5pt]&{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot \mathbf {u} )={\frac {\partial \rho }{\partial t}}+(\nabla \rho )\cdot \mathbf {u} +\rho (\nabla \cdot \mathbf {u} )={\frac {\partial \rho }{\partial t}}+\nabla \cdot (\rho \mathbf {u} )=0\end{aligned}}}
== History == EMP was first synthesized in the mid-1960s and was patented in 1967. It was initially developed for the treatment of breast cancer. The idea for EMP was inspired by the uptake and accumulation of radiolabeled estrogens into breast cancer tissue. However, initial clinical findings of EMP in women with breast cancer were disappointing. Subsequently, radiolabeled EMP was found to be taken up into and accumulated rat prostate gland, and this finding culminated in the medication being repurposed for the treatment of prostate cancer. EMP was introduced for medical use in the treatment of this condition in the early 1970s, and was approved in the United States for this indication in 1981. EMP was originally introduced for use by intravenous injection. Subsequently, an oral formulation was introduced, and the intravenous preparation was almost abandoned in favor of the oral version.
=== Moisture === Excessive and continuous skin moisture can pose a risk to compromise the integrity of the skin by causing the skin tissue to become macerated and therefore be at risk for epidermal erosion. So this category assesses the degree of moisture the skin is exposed to.
Austin debuted in World Championship Wrestling in May 1991. He was nicknamed "Stunning" Steve Austin, a name and gimmick he later said he could not commit to. Austin was originally paired with a valet named Vivacious Veronica but was later joined by Jeannie Adams, known as "Lady Blossom". Just weeks after his debut, Austin defeated Bobby Eaton for his first WCW World Television Championship on June 3, and later that year joined Paul E. Dangerously's Dangerous Alliance. Austin lost the WCW World Television Championship to Barry Windham in a two-out-of-three-falls match on April 27, but regained the championship from Windham the following month. He enjoyed a second lengthy reign as champion, before losing the championship to Ricky Steamboat at Clash of the Champions XX in September 1992, while the Dangerous Alliance disbanded shortly thereafter. In August and September 1992, as part of a working agreement between WCW and New Japan Pro-Wrestling (NJPW), Austin wrestled four matches in Japan. He took part in the 1992 G1 Climax, defeating Arn Anderson in the first round before losing to Keiji Muto in the second round. He and Arn Anderson then defeated Raging Staff (Super Strong Machine and Tatsutoshi Goto) in a tag team bout held in the Ryōgoku Kokugikan in Tokyo. In his final bout, Austin challenged Masahiro Chono for the NWA World Heavyweight Championship in the main event of the "Battle Hold Arena" event at the Yokohama Arena, losing by submission after Chono applied an STF.
== Synthesis == PEDOT:PSS can be prepared by mixing an aqueous solution of PSS with EDOT monomer, and to the resulting mixture, a solution of sodium persulfate and ferric sulfate. The addition of these reagents initiates the oxidative chemical polymerization of EDOT in water to form PEDOT. The stabilizing PSS forms a shell around a core of PEDOT in a nano-sized structure. The negatively charged sulfonic acid ions help stabilize the positively charged PEDOT ions.
Sources: en.wikipedia.org
Diabetes mellitus type 1 is a chronic autoimmune disease in which the immune system attacks the insulin-secreting beta cells of the pancreas. Insulin is needed to keep blood sugar levels within optimal ranges, and its lack can lead to high blood sugar. As an untreated chronic condition, complications including accelerated vascular disease, diabetic retinopathy, kidney disease and neuropathy can result. In addition, if there is not enough insulin for glucose to be used within cells, the medical emergency diabetic ketoacidosis, which is often the first symptom that a person with type 1 diabetes may have, can result. Type 1 diabetes can develop at any age but is most often diagnosed before age 40. For people living with type 1 diabetes, insulin injections are critical for survival. An experimental procedure to treat type 1 diabetes is pancreas transplantation or isolated transplantation of islet cells to supply a person with functioning beta cells.
The Arabia hit a tree snag and sank in the Missouri River on September 5, 1856. All 130 passengers survived, but an estimated 220 tons of cargo went down with it. Shortly thereafter, the river changed course, and the Arabia was buried underground. The cargo, destined for 16 towns on the frontier, was buried under a cornfield in Wyandotte County, Kansas, for 132 years until it was discovered in 1988 by River Salvage Inc., a group of self-proclaimed treasure hunters who began excavations. David, Greg, and Bob Hawley owned a refrigeration repair business. They partnered with Jerry Mackey, owner of Hi-Boy restaurants in Independence, Missouri, and David Lutrell from the construction industry, along with other family and friends, to form River Salvage Inc. With the permission of the land owner, they dug between November 1988 and February 1989. Although their original goal was to sell their discoveries, the historical importance of the finding quickly became apparent, and they started to plan a museum. Today, it is still owned and operated by the Hawley family, who are present there most days, often greeting visitors and answering questions.
... had deteriorated to the point where the Soviet Union as a system—not just the Kremlin, not just Soviet leader Yuri Andropov, not just the KGB, but as a system—was geared to expect an attack and to retaliate very quickly to it. It was on hair-trigger alert. It was very nervous and prone to mistakes and accidents. The false alarm that happened on Petrov's watch could not have come at a more dangerous, intense phase in U.S.–Soviet relations. In an interview aired on American television, Blair said, "The Russians [Soviets] saw a U.S. government preparing for a first strike, headed by a President Ronald Reagan capable of ordering a first strike." Regarding the incident involving Petrov, he said, "I think that this is the closest our country has come to accidental nuclear war."
=== Effects in females === FSH stimulates the growth and recruitment of immature ovarian follicles in the ovary. In early (small) antral follicles, FSH is the major survival factor that rescues the small antral follicles (2–5 mm in diameter for humans) from apoptosis (programmed death of the somatic cells of the follicle and oocyte). In the luteal-follicle phase transition period the serum levels of progesterone and estrogen (primarily estradiol) decrease and no longer suppress the release of FSH, consequently FSH peaks at about day three (day one is the first day of menstrual flow). The cohort of small antral follicles is normally sufficient in number to produce enough Inhibin B to lower FSH serum levels. In addition, there is evidence that gonadotropin surge-attenuating factor produced by small follicles during the first half of the follicle phase also exerts a negative feedback on pulsatile luteinizing hormone (LH) secretion amplitude, thus allowing a more favorable environment for follicle growth and preventing premature luteinization. As a woman nears perimenopause, the number of small antral follicles recruited in each cycle diminishes and consequently insufficient Inhibin B is produced to fully lower FSH and the serum level of FSH begins to rise. Eventually, the FSH level becomes so high that downregulation of FSH receptors occurs and by postmenopause any remaining small secondary follicles no longer have FSH nor LH receptors. When the follicle matures and reaches 8–10 mm in diameter it starts to secrete significant amounts of estradiol.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.